Literature DB >> 19965333

Efficacy and safety of an NRTI-sparing dual regimen of raltegravir and ritonavir-boosted protease inhibitor in a triple antiretroviral class-experienced population.

C Allavena, O Mounoury, A Rodallec, V Reliquet, E Billaud, F Raffi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19965333     DOI： 10.1310/hct1005-337

Source DB:  PubMed          Journal:  HIV Clin Trials        ISSN： 1528-4336


× No keyword cloud information.
  3 in total

1.  HIV Salvage Therapy Does Not Require Nucleoside Reverse Transcriptase Inhibitors: A Randomized, Controlled Trial.

Authors:  Karen T Tashima; Laura M Smeaton; Carl J Fichtenbaum; Adriana Andrade; Joseph J Eron; Rajesh T Gandhi; Victoria A Johnson; Karin L Klingman; Justin Ritz; Sally Hodder; Jorge L Santana; Timothy Wilkin; Richard H Haubrich
Journal:  Ann Intern Med       Date:  2015-11-24       Impact factor: 25.391

2.  Antiretroviral regimens sparing agents from the nucleoside(tide) reverse transcriptase inhibitor class: a review of the recent literature.

Authors:  Amit C Achhra; Mark A Boyd
Journal:  AIDS Res Ther       Date:  2013-12-13       Impact factor: 2.250

3.  Moving away from Ritonavir, Abacavir, Tenofovir, and Efavirenz (RATE)--agents that concern prescribers and patients: a feasibility study and call for a trial.

Authors:  Amit C Achhra; Mark A Boyd; Matthew G Law; Gail V Matthews; Anthony D Kelleher; David A Cooper
Journal:  PLoS One       Date:  2014-06-26       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.